By Cancer Treatment Centers of America®
Cancer Treatment Centers of America® (CTCA) is currently enrolling patients to the Targeted Agent and Profiling Utilization Registry (TAPUR) Study—the American Society of Clinical Oncology’s (ASCO) first-ever clinical trial.
The TAPUR Study is a clinical trial for patients with advanced cancer who have exhausted conventional treatment options and whose genomic test results revealed a tumor mutation that may be targeted with certain anti-cancer drugs. The trial will collect data on how advanced cancer patients respond to drugs not yet approved for that cancer type by the U.S. Food and Drug Administration. The trial offers patients access to drugs, at no cost to them, affording them new treatment options and opening an important window into how certain drugs perform on specific mutations.
According to Dr. Maurie Markman, President of Medicine and Science at CTCA®, “This trial changes the entire language of clinical research in cancer. Rather than base treatments on large populations of patients, we are looking at the individual patient’s tumor. This is the future of cancer research.”
How can patients qualify for this study?
CLICK HERE TO FIND OUT MORE
About Dr. Maurie Markman
A nationally-renowned oncologist, Dr. Maurie Markman is President of Medicine and Science at Cancer Treatment Centers of America. Previously, he was Senior Vice President of Clinical Affairs and National Director of Medical Oncology. Dr. Markman has more than 20 years of experience in cancer treatment and gynecologic research at some of the country’s most recognized facilities, including M.D. Anderson Cancer Center in Houston Texas and the Taussig Cancer Center at the Cleveland Clinic Foundation.
About Cancer Treatment Centers of America
Cancer Treatment Centers of America® (CTCA) is a national network of five hospitals that serves adult patients who are fighting cancer. CTCA® offers an integrative approach to care that combines advancements in genomic testing and precision cancer treatment, surgery, radiation, immunotherapy and chemotherapy, with evidence-informed supportive therapies designed to help patients physically and emotionally by enhancing their quality of life while managing side effects both during and after treatment. Visit www.cancercenter.com for more info. You may also reach them at 1-800-227-3207 with any questions.
Stay up to date on all things CTCA! Be sure to follow them on Facebook, Instagram, Twitter, Pinterest, LinkedIn and YouTube.
